According to ESMO guidelines, in a man with metastatic castration‑resistant prostate cancer who has progressed on androgen‑signaling blockade, what criteria determine the choice between ^177Lu‑PSMA‑617 radioligand therapy and taxane chemotherapy (docetaxel or cabazitaxel)?

When to Choose Radioligand Therapy vs Chemotherapy in mCRPC

According to 2023 ESMO guidelines, both ^177Lu-PSMA-617 and cabazitaxel are equally recommended (Level I, A evidence) as third-line options for mCRPC patients who have progressed on both an androgen receptor pathway inhibitor and docetaxel, with the choice determined primarily by PSMA expression on PET imaging. 1

Treatment Selection Algorithm

Prerequisites for Either Therapy

Both options require:

• Prior treatment with both a novel androgen receptor axis inhibitor (abiraterone, apalutamide, darolutamide, or enzalutamide) and docetaxel 1
• Patient fitness to tolerate treatment 1

Choose ^177Lu-PSMA-617 When:

• PSMA-PET imaging shows:

  • Cancer expressing PSMA on PET-PSMA imaging AND
  • No PSMA non-expressing lesions (this is critical) 1

• Advantages:

  • Higher ESMO-MCBS score (4 vs 3 for cabazitaxel) 1
  • Superior PSA response rates (66% vs 37-44%) 2, 3
  • Significantly improved overall survival (HR 0.62; median 15.3 vs 11.3 months) 1
  • Fewer grade 3-4 adverse events (33% vs 53%) 2
  • Better quality of life outcomes 3

Choose Cabazitaxel When:

• PSMA-PET imaging shows:

  • PSMA-negative lesions present OR
  • FDG-positive but PSMA-negative discordant disease

• Patient cannot access PSMA-PET imaging (cabazitaxel doesn't require companion diagnostic)

• Practical considerations:

  • No access to nuclear medicine facilities for radioligand therapy
  • Patient preference for chemotherapy

Critical Imaging Requirements

For ^177Lu-PSMA-617 eligibility, you must document:

• Gallium-68 [^68Ga]Ga-PSMA-11 PET/CT showing PSMA-avid disease
• Lesion-to-liver uptake ratio >1 (VISION trial criteria) 2
• Absence of PSMA-negative/FDG-positive discordant lesions 2

Common pitfall: If using ^99mTc-MIP-1404 SPECT instead of ^68Ga-PSMA-11 PET, apply a lower lesion-to-liver threshold due to higher liver background activity with this tracer 4

Evidence Quality Comparison

The ESMO guideline assigns ^177Lu-PSMA-617 a higher clinical benefit score (ESMO-MCBS 4) compared to cabazitaxel (ESMO-MCBS 3) 1. This reflects:

• 4-month absolute OS gain (HR 0.62) 1
• Superior radiographic PFS (HR 0.40; 8.7 vs 3.4 months) 1
• More favorable toxicity profile 2

The TheraP trial directly compared these agents head-to-head, demonstrating ^177Lu-PSMA-617's superiority in PSA response (66% vs 37%, p<0.0001) with significantly fewer grade 3-4 adverse events 2.

Special Considerations

If patient is chemotherapy-naïve: Recent evidence suggests ^177Lu-PSMA-617 may be non-inferior to docetaxel even as second-line therapy 3, though ESMO guidelines currently recommend it after both androgen receptor inhibitor and taxane failure 1.

Toxicity profiles differ substantially:

• ^177Lu-PSMA-617: Primarily dry mouth, fatigue, bone marrow suppression (manageable) 2, 5
• Cabazitaxel: Neutropenia requiring G-CSF, diarrhea, neuropathy 6, 2

The presence of any PSMA-negative lesions is an absolute contraindication to radioligand therapy as these sites will not respond and may drive progression 1.